Neurotech
Founded Year
1995Stage
Acquired | AcquiredTotal Raised
$73.87MAbout Neurotech
Neurotech is a spin-off of the UniversitA© catholique de Louvain and has been funded by SOPARTEC, the technology transfer company of UniversitA© catholique de Louvain, Vives Louvain Technology Fund SA and SRIW Techno SA (SociA©tA© RA©gionale d'Investissement de Wallonie). Neurotech designs and develops implantable medical devices for the treatment of debilitating disorders by neurostimulation. Neurotech's first developed product, an implantable vagus nerve stimulator, presents two key differentiators: the ADNS-300 uses a rechargeable battery and not only stimulates the vagus nerve but also records neural activity from the left vagus nerve using an innovative cuff electrode. This unique sensing feature enables the physician to capture the "compound action potential" (CAP) generated by the stimulation, which should allow an improved and personalized treatment. In November 2012, Neurotech was acquired by Sorin Group. The valuation of Neurotech was undisclosed. Other terms of the deal were not released.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Neurotech Patents
Neurotech has filed 16 patents.
The 3 most popular patent topics include:
- Biomolecules
- Biotechnology
- Heart diseases
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/27/2016 | 10/29/2019 | Diseases of the eye and adnexa, Monoclonal antibodies, Ophthalmology, Experimental cancer drugs, Disorders of choroid and retina | Grant |
Application Date | 5/27/2016 |
|---|---|
Grant Date | 10/29/2019 |
Title | |
Related Topics | Diseases of the eye and adnexa, Monoclonal antibodies, Ophthalmology, Experimental cancer drugs, Disorders of choroid and retina |
Status | Grant |
Latest Neurotech News
Sep 5, 2023
hapabapa Neurotech company Helius Medical Technologies (NASDAQ: HSDT ) said on Tuesday that it has regained compliance with Nasdaq's minimum bid price requirement. The company said it has received a formal notice from the listing qualifications staff of the stock exchange on the matter, and the matter is now closed. The news comes after the company announced a 1-for-50 reverse stock split.
Neurotech Frequently Asked Questions (FAQ)
When was Neurotech founded?
Neurotech was founded in 1995.
What is Neurotech's latest funding round?
Neurotech's latest funding round is Acquired.
How much did Neurotech raise?
Neurotech raised a total of $73.87M.
Who are the investors of Neurotech?
Investors of Neurotech include LivaNova, Apax Partners, Atlas Venture, Excalibur Fund Managers, 3i Group and 30 more.
Who are Neurotech's competitors?
Competitors of Neurotech include Hawaii Biotech, Ocera Therapeutics, Aduro BioTech, Ascendis Pharma, Potentia Pharmaceuticals and 12 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Neurotech to Competitors
TechnoVax is a privately held biotechnology company and specializes in vaccine development. The company aims to begin clinical trials within the next 18 months.
Hawaii Biotech (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development.
M8 Pharmaceuticals is a pharmaceutical company. The company's services are provided by partnering with pharmaceutical companies looking to establish, maintain, or expand their business presence due to their understanding of the regulatory complexities, stringent quality assurance, and adherence to international standards, enabling people to get proven therapies. It was founded in 2007 and is based in Berwyn, Pennsylvania.
Osprey Pharmaceuticals is a privately held biotechnology company focused on developing and commercializing a first-in-class family of therapeutic proteins (Leukocyte Population Modulators) capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The company's proprietary LPMs selectively and systematically destroy disease-related leukocytes by infiltrating the chemokine system that regulates the movement and activity of leukocytes.
ProtAffin is a pre-clinical biotechnology company developing protein-based products countering inflammation. Its biologics targets the heparin-like glycan structures that drive inflammatory processes.
greenovation Biotech GmbH is engaged in the production of pharmaceutically highly-efficient glycoproteins
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
